KR102572626B1 - 테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법 - Google Patents

테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법 Download PDF

Info

Publication number
KR102572626B1
KR102572626B1 KR1020177006422A KR20177006422A KR102572626B1 KR 102572626 B1 KR102572626 B1 KR 102572626B1 KR 1020177006422 A KR1020177006422 A KR 1020177006422A KR 20177006422 A KR20177006422 A KR 20177006422A KR 102572626 B1 KR102572626 B1 KR 102572626B1
Authority
KR
South Korea
Prior art keywords
formula
compound
acid
mixture
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177006422A
Other languages
English (en)
Korean (ko)
Other versions
KR20170102204A (ko
Inventor
존 포드
요하네스 파울루스 게라르두스 세르덴
아만딘 레드루
Original Assignee
뉴암스테르담 파마 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51429345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102572626(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 뉴암스테르담 파마 비.브이. filed Critical 뉴암스테르담 파마 비.브이.
Publication of KR20170102204A publication Critical patent/KR20170102204A/ko
Application granted granted Critical
Publication of KR102572626B1 publication Critical patent/KR102572626B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177006422A 2014-08-12 2015-07-29 테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법 Active KR102572626B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2014050556 2014-08-12
NLPCT/NL2014/050556 2014-08-12
PCT/NL2015/050555 WO2016024858A1 (en) 2014-08-12 2015-07-29 Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Publications (2)

Publication Number Publication Date
KR20170102204A KR20170102204A (ko) 2017-09-08
KR102572626B1 true KR102572626B1 (ko) 2023-08-30

Family

ID=51429345

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177006422A Active KR102572626B1 (ko) 2014-08-12 2015-07-29 테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법

Country Status (28)

Country Link
US (1) US10112904B2 (https=)
EP (2) EP3180314B1 (https=)
JP (1) JP6670310B2 (https=)
KR (1) KR102572626B1 (https=)
CN (1) CN107108558B (https=)
AR (1) AR101509A1 (https=)
AU (1) AU2015302407B2 (https=)
BR (1) BR112017002873B1 (https=)
CA (1) CA2958040C (https=)
CL (1) CL2017000367A1 (https=)
CY (1) CY1125574T1 (https=)
DK (1) DK3180314T3 (https=)
EA (1) EA034357B1 (https=)
ES (1) ES2926775T3 (https=)
HR (1) HRP20221061T1 (https=)
HU (1) HUE059947T2 (https=)
IL (1) IL250525B (https=)
LT (1) LT3180314T (https=)
MA (1) MA40378B1 (https=)
MX (1) MX367908B (https=)
PL (1) PL3180314T3 (https=)
PT (1) PT3180314T (https=)
RS (1) RS63575B1 (https=)
SG (1) SG11201701077XA (https=)
SI (1) SI3180314T1 (https=)
SM (1) SMT202200385T1 (https=)
TW (1) TWI691490B (https=)
WO (1) WO2016024858A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4125911B1 (en) 2021-03-05 2024-04-24 NewAmsterdam Pharma B.V. Obicetrapib for treatment of dementias
IL310115A (en) 2021-07-26 2024-03-01 Newamsterdam Pharma B V Treatment of his hyporesponders
AU2022425078A1 (en) 2021-12-30 2024-08-08 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
CU20250001A7 (es) 2022-07-05 2025-10-17 Newamsterdam Pharma B V Sales de obicetrapib y procesos para su fabricación y productos intermedios de estos
TW202416994A (zh) 2022-08-22 2024-05-01 荷蘭商新阿姆斯特丹製藥公司 固定劑量醫藥組合物及其用途
EP4661865A1 (en) 2023-02-07 2025-12-17 NewAmsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025059594A1 (en) 2023-09-15 2025-03-20 Newamsterdam Pharma B.V. METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093436A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025146262A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies
WO2025146415A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Improvement in atherosclerotic plaque characteristics with obicetrapib
WO2026062050A1 (en) 2024-09-17 2026-03-26 Newamsterdam Pharma B.V. Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd)
WO2026062049A1 (en) 2024-09-21 2026-03-26 Newamsterdam Pharma B.V., Obicetrapib for the treatment of dementias
WO2026063944A1 (en) 2024-09-21 2026-03-26 Newamsterdam Pharma B.V. Obicetrapib for the treatment of dementias

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017164A1 (en) 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
WO2007116922A1 (en) * 2006-03-30 2007-10-18 Mitsubishi Tanabe Pharma Corporation A process for preparing tetrahydroquinoline derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE316957T1 (de) * 2001-04-30 2006-02-15 Pfizer Prod Inc Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
CN101466679A (zh) * 2006-03-30 2009-06-24 田边三菱制药株式会社 制备四氢喹啉衍生物的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017164A1 (en) 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
KR100428330B1 (ko) 1998-09-17 2004-04-28 화이자 프로덕츠 인코포레이티드 Cetp 저해제로서 4-카복시아미노-2-치환된-1,2,3,4-테트라하이드로퀴놀린
WO2007116922A1 (en) * 2006-03-30 2007-10-18 Mitsubishi Tanabe Pharma Corporation A process for preparing tetrahydroquinoline derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ana Escribano 외, Bioorganic & Medicinal Chemistry Letters, 2012년, Vol.22, No.11, pp.3671-3675*
Dan Huang 외, RSC Advances, 2013년, Vol.3, No.2, pp.573-578*
David B. Damon 외, Organic Process Research & Development, 2006년, Vol.10, No.3, pp.464-471*
KOUZNETSOV et al., TETRAHEDRON, 2009년, Vol.65, No.14, pp.2721-2750

Also Published As

Publication number Publication date
JP6670310B2 (ja) 2020-03-18
PT3180314T (pt) 2022-09-02
EP4083022A1 (en) 2022-11-02
EP3180314A1 (en) 2017-06-21
IL250525A0 (en) 2017-03-30
CA2958040A1 (en) 2016-02-18
MX2017001930A (es) 2018-03-01
HRP20221061T1 (hr) 2022-11-25
CN107108558B (zh) 2019-11-19
CN107108558A (zh) 2017-08-29
EA201790364A1 (ru) 2017-07-31
DK3180314T3 (da) 2022-08-29
HUE059947T2 (hu) 2023-01-28
IL250525B (en) 2019-08-29
SI3180314T1 (sl) 2022-11-30
JP2017524742A (ja) 2017-08-31
AU2015302407A1 (en) 2017-03-02
AR101509A1 (es) 2016-12-21
TW201613868A (en) 2016-04-16
MX367908B (es) 2019-09-11
CY1125574T1 (el) 2026-02-25
SG11201701077XA (en) 2017-03-30
MA40378A (fr) 2017-06-21
WO2016024858A1 (en) 2016-02-18
MA40378B1 (fr) 2022-10-31
CL2017000367A1 (es) 2018-02-09
BR112017002873A2 (pt) 2018-07-17
LT3180314T (lt) 2022-11-10
CA2958040C (en) 2022-09-13
KR20170102204A (ko) 2017-09-08
US20170267640A1 (en) 2017-09-21
BR112017002873B1 (pt) 2023-03-28
PL3180314T3 (pl) 2022-11-21
RS63575B1 (sr) 2022-10-31
AU2015302407B2 (en) 2019-09-19
BR112017002873A8 (pt) 2022-11-08
ES2926775T3 (es) 2022-10-28
TWI691490B (zh) 2020-04-21
SMT202200385T1 (it) 2022-11-18
US10112904B2 (en) 2018-10-30
EA034357B1 (ru) 2020-01-30
EP3180314B1 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
KR102572626B1 (ko) 테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법
US20240166605A1 (en) Process for the preparation of a pde4 inhibitor
US20090163738A1 (en) Process to prepare treprostinil, the active ingredient in remodulin
US8198485B2 (en) Resolution of 4,5-dimethoxy-1-(methylaminomenthyl)-benzocyclobutane
ES2756000T3 (es) Nuevo procedimiento
CN101570510A (zh) 喹啉类化合物及其药物组合物、制备方法和应用
CN118047774A (zh) 一种制备非奈利酮及其中间体的方法
WO2009062036A2 (en) Processes for preparing levocetirizine and pharmaceutically acceptable salts thereof
US9828340B2 (en) Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide
WO2013106756A2 (en) Antimicrobial agents
JP2016164143A (ja) Ｈｃｖの大環状プロテアーゼ阻害剤の製造のための方法及び中間体
BE897000A (fr) Nouveaux derives de la 1,4-dihydropyridine,leur preparation et leur utilisation comme medicaments
HK40081593A (en) Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
CA2267247C (fr) Heteroaryloxyethylamines en tant que ligands 5-ht1a
AU2004290695A1 (en) Processes for the preparation of N-substituted phthalimides
AU2010277144A1 (en) Polymorphic form of toremifene citrate and process for its preparation
ZA200702457B (en) Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands
US6433174B1 (en) Process for producing novel naphthyridine derivatives
HK1239687A1 (en) Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
US20040122099A1 (en) Process for preparing S-(2-aminoethyl)-2-methyl-L-cysteine
US20100174073A1 (en) Process for the preparation of alfuzosin and salts thereof
HK1239687B (zh) 制备用於制备四氢喹啉衍生物的合成中间体的方法
BE893095Q (fr) Phenylpiperidines leur preparation et leur utilisation
WO2014020546A2 (en) Crystalline forms of dabigatran etexilate and process for their preparation

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601